Clemens van Blitterswijk: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
mNo edit summary
mNo edit summary
Line 25: Line 25:


== Career ==
== Career ==
van Blitterswijk graduated as cell biologist at [[Leiden University]] in 1982. He defended his PhD thesis in 1985 at the same university on artificial ceramic middle ear implants under the supervision of the ceramic bioengineering [[Klaas de Groot|Klaas De Groot]], for which he was awarded the Jean Leray young scientist award of the [[European Society for Biomaterials]]. In the 1990s, he worked on biomaterials to heal bone injuries at [[Leiden University]] and then as the CEO of IsoTis, a former publicly traded life sciences company that he co-founded along with [[Klaas de Groot|Klaas De Groot]]. In 2003, he became professor at [[University of Twente]], where he later participated to the foundation and directed the former MIRA institute that became part of the [https://www.utwente.nl/en/techmed/ Technical Medical Center.] There, with [https://www.tue.nl/en/research/researchers/jan-de-boer/ Jan de Boer], [https://www.ndcs.com.sg/research-innovation/our-researchers/hemant-vijaykumar-unadkat Hemant Unadkat], and other collaborators<ref name=":0" />, he used more systematic and high-throughput approaches to select micrometer-scale surface textures of biomaterials aimed at enhancing specific cellular functions (for example osteoinduction), which resulted in the TopoChip.<ref>{{cite journal | vauthors = Unadkat HV, Hulsman M, Cornelissen K, Papenburg BJ, Truckenmüller RK, Carpenter AE, Wessling M, Post GF, Uetz M, Reinders MJ, Stamatialis D, van Blitterswijk CA, de Boer J | title = An algorithm-based topographical biomaterials library to instruct cell fate | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 108 | issue = 40 | pages = 16565–70 | date = October 2011 | pmid = 21949368 | pmc = 3189082 | doi = 10.1073/pnas.1109861108 }}</ref><ref>{{cite journal | vauthors = Baker M | title = Trying out topographies | journal = Nature Methods | volume = 8 | issue = 11 | pages = 900 | date = November 2011 | pmid = 22167818 | doi = 10.1038/nmeth.1760 }}</ref><ref name=":0" /> In 2014, he became a distinguished professors at [[Maastricht University]] (UM).<ref>{{Cite web|url=https://www.maastrichtuniversity.nl/research/distinguished-university-professors|title=Distinguished university professors – Research – Maastricht University|website=maastrichtuniversity.nl|access-date=1 February 2018}}</ref> Between 2014 and 2018, he acted as the institute director and department chair at the [https://merlninstitute.com/ MERLN Institute for Technology-Inspired Regenerative Medicine] at [[Maastricht University]]. In 2015, he was awarded an [[European Research Council|ERC]] Advanced grant that aimed at developing [[Microfabrication|microfabricated]] and [[Microfluidic cell culture|microfluidic]] cell culture platforms for improving mouse [[Organoid|organoids]] reflective of the [[Pancreatic islets|pancreatic islet]], the [[pituitary gland]], and the [[Gastruloid|embryo]].<ref>{{cite web|title=Press release Maastricht University|url=https://www.maastrichtuniversity.nl/news/major-european-grant-professor-clemens-van-blitterswijk|last=|first=|date=8 April 2016|website=Maastricht University|url-status=live|archive-url=|archive-date=|access-date=}}</ref> In 2017, he received a NWO Gravitation grant<ref>{{cite web|title=Gravitation|url=https://www.nwo.nl/en/funding/our-funding-instruments/nwo/gravitation/gravitation.html|website=nwo.nl}}</ref>. In 2018 he founded an international consortium ([https://regmedxb.com/ Regenerative Medicine Crossing Borders; RegMed XB])<ref>{{cite web|url=https://regmedxb.com/|title=Home – RegMed XB – Regenerative medicine crossing borders|website=regmedxb.com}}</ref> that aims to bring multiple cures for chronic diseases to market in the next ten years.
van Blitterswijk graduated as cell biologist at [[Leiden University]] in 1982. He defended his PhD thesis in 1985 at the same university on artificial ceramic middle ear implants under the supervision of the ceramic bioengineering [[Klaas de Groot|Klaas De Groot]], for which he was awarded the Jean Leray young scientist award of the [[European Society for Biomaterials]]. In the 1990s, he worked on biomaterials to heal bone injuries at [[Leiden University]] and then as the CEO of IsoTis, a former publicly traded life sciences company that he co-founded along with [[Klaas de Groot|Klaas De Groot]]. In 2003, in parallel to his position as a CEO of IsoTis, he became professor at [[University of Twente]], where he later participated to the foundation and directed the former MIRA institute that became part of the [https://www.utwente.nl/en/techmed/ Technical Medical Center.] There, with [https://www.tue.nl/en/research/researchers/jan-de-boer/ Jan de Boer], [https://www.ndcs.com.sg/research-innovation/our-researchers/hemant-vijaykumar-unadkat Hemant Unadkat], and other collaborators<ref name=":0" />, he used more systematic and high-throughput approaches to select micrometer-scale surface textures of biomaterials aimed at enhancing specific cellular functions (for example osteoinduction), which resulted in the TopoChip.<ref>{{cite journal | vauthors = Unadkat HV, Hulsman M, Cornelissen K, Papenburg BJ, Truckenmüller RK, Carpenter AE, Wessling M, Post GF, Uetz M, Reinders MJ, Stamatialis D, van Blitterswijk CA, de Boer J | title = An algorithm-based topographical biomaterials library to instruct cell fate | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 108 | issue = 40 | pages = 16565–70 | date = October 2011 | pmid = 21949368 | pmc = 3189082 | doi = 10.1073/pnas.1109861108 }}</ref><ref>{{cite journal | vauthors = Baker M | title = Trying out topographies | journal = Nature Methods | volume = 8 | issue = 11 | pages = 900 | date = November 2011 | pmid = 22167818 | doi = 10.1038/nmeth.1760 }}</ref><ref name=":0" /> In 2012, he became a partner of the firm [https://www.lspvc.com/team/clemens-van-blitterswijk.html Health Economics Funds (HEF) of the European health care investment group Life Sciences Partners] (LSP). His prime focus and responsibility within LSP is to invest in private companies. In 2014, he left [[University of Twente|Twente University]] and became a distinguished professors at [[Maastricht University]] (UM), while maintaining his activities at [https://www.lspvc.com/team/clemens-van-blitterswijk.html LSP].<ref>{{Cite web|url=https://www.maastrichtuniversity.nl/research/distinguished-university-professors|title=Distinguished university professors – Research – Maastricht University|website=maastrichtuniversity.nl|access-date=1 February 2018}}</ref> Between 2014 and 2018, he acted as the institute director and department chair at the [https://merlninstitute.com/ MERLN Institute for Technology-Inspired Regenerative Medicine] at [[Maastricht University]]. In 2015, he was awarded an [[European Research Council|ERC]] Advanced grant that aimed at developing [[Microfabrication|microfabricated]] and [[Microfluidic cell culture|microfluidic]] cell culture platforms for improving mouse [[Organoid|organoids]] reflective of the [[Pancreatic islets|pancreatic islet]], the [[pituitary gland]], and the [[Gastruloid|embryo]].<ref>{{cite web|title=Press release Maastricht University|url=https://www.maastrichtuniversity.nl/news/major-european-grant-professor-clemens-van-blitterswijk|last=|first=|date=8 April 2016|website=Maastricht University|url-status=live|archive-url=|archive-date=|access-date=}}</ref> In 2017, he received a NWO Gravitation grant<ref>{{cite web|title=Gravitation|url=https://www.nwo.nl/en/funding/our-funding-instruments/nwo/gravitation/gravitation.html|website=nwo.nl}}</ref>. In 2018 he founded an international consortium ([https://regmedxb.com/ Regenerative Medicine Crossing Borders; RegMed XB])<ref>{{cite web|url=https://regmedxb.com/|title=Home – RegMed XB – Regenerative medicine crossing borders|website=regmedxb.com}}</ref> that aims to bring multiple cures for chronic diseases to market in the next ten years.


He is a fellow of the [https://fellowsbse.org/ International Union of Societies for Biomaterials Science and Engineering].<ref>{{cite web|url=https://fellowsbse.org/|title=HOME|last=nnadilim}}</ref> He has been a member of the [https://www.acti-nl.org/ Netherlands Academy of Technology and Innovation] (AcTI)<ref>https://www.acti-nl.org/en/homepage?set_language=en since</ref> since 2003, the [https://www.knaw.nl/en Royal Netherlands Academy of Arts and Sciences] ([[Royal Netherlands Academy of Arts and Sciences|KNAW]]) since 2012, and the [http://www.khmw.nl/ Royal Holland Society of Sciences and Humanities] (KHMW)<ref>https://khmw.nl/</ref> since 2016. He is part of the editorial board of the ''[https://onlinelibrary.wiley.com/journal/19327005 Journal of Tissue Engineering and Regenerative Medicine]''.<ref>{{cite journal|url=https://onlinelibrary.wiley.com/journal/19327005|title=Journal of Tissue Engineering and Regenerative Medicine – Wiley Online Library|journal=Journal of Tissue Engineering and Regenerative Medicine|doi=10.1002/(issn)1932-7005|doi-access=free}}</ref>
He is a fellow of the [https://fellowsbse.org/ International Union of Societies for Biomaterials Science and Engineering].<ref>{{cite web|url=https://fellowsbse.org/|title=HOME|last=nnadilim}}</ref> He has been a member of the [https://www.acti-nl.org/ Netherlands Academy of Technology and Innovation] (AcTI)<ref>https://www.acti-nl.org/en/homepage?set_language=en since</ref> since 2003, the [https://www.knaw.nl/en Royal Netherlands Academy of Arts and Sciences] ([[Royal Netherlands Academy of Arts and Sciences|KNAW]]) since 2012, and the [http://www.khmw.nl/ Royal Holland Society of Sciences and Humanities] (KHMW)<ref>https://khmw.nl/</ref> since 2016. He is part of the editorial board of the ''[https://onlinelibrary.wiley.com/journal/19327005 Journal of Tissue Engineering and Regenerative Medicine]''.<ref>{{cite journal|url=https://onlinelibrary.wiley.com/journal/19327005|title=Journal of Tissue Engineering and Regenerative Medicine – Wiley Online Library|journal=Journal of Tissue Engineering and Regenerative Medicine|doi=10.1002/(issn)1932-7005|doi-access=free}}</ref>
Line 33: Line 33:
He has been named the most entrepreneurial scientist in the Netherlands in 2012<ref>{{Cite web|url=https://www.utwente.nl/en/news/!/2012/6/260057/van-blitterswijk-voted-most-entrepreneurial-scientist-of-the-netherlands|title=News_van Blitterswijk most entrepreneurial scientist in 2012|website=|access-date=1 February 2018}}</ref> and receiving the Huibregtsen award<ref name="avondwenm.nl">{{cite web|url=http://www.avondwenm.nl/huibregtsenprijs/over-de-prijs|title=Over de prijs|website=avondwenm.nl}}</ref> for ground-breaking science with societal impact in 2015.
He has been named the most entrepreneurial scientist in the Netherlands in 2012<ref>{{Cite web|url=https://www.utwente.nl/en/news/!/2012/6/260057/van-blitterswijk-voted-most-entrepreneurial-scientist-of-the-netherlands|title=News_van Blitterswijk most entrepreneurial scientist in 2012|website=|access-date=1 February 2018}}</ref> and receiving the Huibregtsen award<ref name="avondwenm.nl">{{cite web|url=http://www.avondwenm.nl/huibregtsenprijs/over-de-prijs|title=Over de prijs|website=avondwenm.nl}}</ref> for ground-breaking science with societal impact in 2015.


He is a founding partner of the Health Economics Funds (HEF) of the European health care investment group Life Sciences Partners<ref>{{cite web|url=https://www.lspvc.com/|title=HOME|website=lspvc.com}}</ref> (LSP), a healthcare investment firms in Europe. The two HEF funds<ref>{{cite web|url=https://www.lspvc.com/funds/hef.html|title=FUNDS >> Private Franchise|website=lspvc.com}}</ref> have raised close to €400&nbsp;million for technologies that aim at improving the quality of health care while lowering the cost of it, focused specifically on medical devices, diagnostics, and digital health. HEF2, at €280&nbsp;million, is currently one of the largest fund in Europe dedicated to medical technology.
He is a partner of the Health Economics Funds (HEF) of the European health care investment group Life Sciences Partners<ref>{{cite web|url=https://www.lspvc.com/|title=HOME|website=lspvc.com}}</ref> (LSP), a healthcare investment firms in Europe. The two HEF funds<ref>{{cite web|url=https://www.lspvc.com/funds/hef.html|title=FUNDS >> Private Franchise|website=lspvc.com}}</ref> have raised close to €400&nbsp;million for technologies that aim at improving the quality of health care while lowering the cost of it, focused specifically on medical devices, diagnostics, and digital health. HEF2, at €280&nbsp;million, is currently one of the largest fund in Europe dedicated to medical technology.


== Teaching ==
== Teaching ==

Revision as of 19:34, 25 May 2020

Clemens van Blitterswijk
Clemens van Blitterswijk
Born1957
The Hague, Netherlands
Nationality Netherlands
Alma materUniversity of Leiden
AwardsJean Leray Award;

The Marie Parijs Award; The Klein Award;

George Winter Award; Huibregtsen Prize; Career Achievement Award;
Scientific career
FieldsBiomedical engineering, biomaterials, tissue engineering
InstitutionsUniversity of Maastricht

Clemens A. van Blitterswijk (1957, The Hague) is a Dutch scientist in tissue engineering, a field that aims to replace or regenerate diseased or damaged tissues through a combination of biology and engineering. He has contributed to the use of synthetic biomaterials to heal bone injuries, especially to an approach termed osteoinduction that aims at designing biomaterials that upon implantation trigger the surrounding cells to form new bone tissue.[1] One example of this contribution is a paper published along with Joost de Bruijn and Huipin Yuan.[2] Following other laboratories[3], and with Jan de Boer, Hemant Unadkat, and other collaborators[4], he has contributed to apply high-throughput techniques to design biomaterials, an approach termed materiomics. The scientific publications that include him as an author can be found here.

Career

van Blitterswijk graduated as cell biologist at Leiden University in 1982. He defended his PhD thesis in 1985 at the same university on artificial ceramic middle ear implants under the supervision of the ceramic bioengineering Klaas De Groot, for which he was awarded the Jean Leray young scientist award of the European Society for Biomaterials. In the 1990s, he worked on biomaterials to heal bone injuries at Leiden University and then as the CEO of IsoTis, a former publicly traded life sciences company that he co-founded along with Klaas De Groot. In 2003, in parallel to his position as a CEO of IsoTis, he became professor at University of Twente, where he later participated to the foundation and directed the former MIRA institute that became part of the Technical Medical Center. There, with Jan de Boer, Hemant Unadkat, and other collaborators[4], he used more systematic and high-throughput approaches to select micrometer-scale surface textures of biomaterials aimed at enhancing specific cellular functions (for example osteoinduction), which resulted in the TopoChip.[5][6][4] In 2012, he became a partner of the firm Health Economics Funds (HEF) of the European health care investment group Life Sciences Partners (LSP). His prime focus and responsibility within LSP is to invest in private companies. In 2014, he left Twente University and became a distinguished professors at Maastricht University (UM), while maintaining his activities at LSP.[7] Between 2014 and 2018, he acted as the institute director and department chair at the MERLN Institute for Technology-Inspired Regenerative Medicine at Maastricht University. In 2015, he was awarded an ERC Advanced grant that aimed at developing microfabricated and microfluidic cell culture platforms for improving mouse organoids reflective of the pancreatic islet, the pituitary gland, and the embryo.[8] In 2017, he received a NWO Gravitation grant[9]. In 2018 he founded an international consortium (Regenerative Medicine Crossing Borders; RegMed XB)[10] that aims to bring multiple cures for chronic diseases to market in the next ten years.

He is a fellow of the International Union of Societies for Biomaterials Science and Engineering.[11] He has been a member of the Netherlands Academy of Technology and Innovation (AcTI)[12] since 2003, the Royal Netherlands Academy of Arts and Sciences (KNAW) since 2012, and the Royal Holland Society of Sciences and Humanities (KHMW)[13] since 2016. He is part of the editorial board of the Journal of Tissue Engineering and Regenerative Medicine.[14]

Valorization

Since the 1990s, he has focused on translating technologies to commercial products. He is registered on 34 patents.[15] He has contributed to several companies and served as CEO (from 1996 to 2002) of IsoTis[16]. IsoTis subsequently suffered heavy financial losses and was on the verge of bankruptcy before merging with Integra LifeSciences.[17][18] He became the chairman of Kuros in June 2018[19].

He has been named the most entrepreneurial scientist in the Netherlands in 2012[20] and receiving the Huibregtsen award[21] for ground-breaking science with societal impact in 2015.

He is a partner of the Health Economics Funds (HEF) of the European health care investment group Life Sciences Partners[22] (LSP), a healthcare investment firms in Europe. The two HEF funds[23] have raised close to €400 million for technologies that aim at improving the quality of health care while lowering the cost of it, focused specifically on medical devices, diagnostics, and digital health. HEF2, at €280 million, is currently one of the largest fund in Europe dedicated to medical technology.

Teaching

Over his 30-year career, he has been the official supervisor of over 70 PhD candidates who worked as researchers within the laboratories of several principal investigators at the universities of Twente and Maastricht. He has participated to the edition of four textbooks, including one dedicated to tissue engineering.[24]

Awards

He has been awarded the following pizes:

  • George Winter senior scientist award[25]
  • Career Achievement award of the EU Chapter of the Tissue Engineering and Regenerative Medicine International Society[26]
  • Federa award[27] for a major contribution in medical research
  • Huibregtsen award[21] for ground-breaking science with societal impact

Ten Major Publications

  • Levenberg S, Rouwkema J, Macdonald M, Garfein ES, Kohane DS, Darland DC, Marini R, van Blitterswijk CA, Mulligan RC, D'Amore PA, Langer R (July 2005). "Engineering vascularized skeletal muscle tissue". Nature Biotechnology. 23 (7): 879–84. doi:10.1038/nbt1109. PMID 15965465.
  • Moroni L, de Wijn JR, van Blitterswijk CA (March 2006). "3D fiber-deposited scaffolds for tissue engineering: influence of pores geometry and architecture on dynamic mechanical properties". Biomaterials. 27 (7): 974–85. doi:10.1016/j.biomaterials.2005.07.023. PMID 16055183.
  • Rouwkema J, de Boer J, Van Blitterswijk CA (September 2006). "Endothelial cells assemble into a 3-dimensional prevascular network in a bone tissue engineering construct". Tissue Engineering. 12 (9): 2685–93. doi:10.1089/ten.2006.12.2685. PMID 16995802.
  • Meijer GJ, de Bruijn JD, Koole R, van Blitterswijk CA (February 2007). "Cell-based bone tissue engineering". PLOS Medicine. 4 (2): e9. doi:10.1371/journal.pmed.0040009. PMC 1800310. PMID 17311467.{{cite journal}}: CS1 maint: unflagged free DOI (link)</ref>
  • Jukes JM, Both SK, Leusink A, Sterk LM, van Blitterswijk CA, de Boer J (May 2008). "Endochondral bone tissue engineering using embryonic stem cells". Proceedings of the National Academy of Sciences of the United States of America. 105 (19): 6840–5. doi:10.1073/pnas.0711662105. PMC 2374550. PMID 18467492.
  • Siddappa R, Martens A, Doorn J, Leusink A, Olivo C, Licht R, van Rijn L, Gaspar C, Fodde R, Janssen F, van Blitterswijk C, de Boer J (May 2008). "cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo". Proceedings of the National Academy of Sciences of the United States of America. 105 (20): 7281–6. doi:10.1073/pnas.0711190105. PMC 2387183. PMID 18490653.
  • Yuan H, Fernandes H, Habibovic P, de Boer J, Barradas AM, de Ruiter A, Walsh WR, van Blitterswijk CA, de Bruijn JD (August 2010). "Osteoinductive ceramics as a synthetic alternative to autologous bone grafting". Proceedings of the National Academy of Sciences of the United States of America. 107 (31): 13614–9. doi:10.1073/pnas.1003600107. PMC 2922269. PMID 20643969.
  • Unadkat HV, Hulsman M, Cornelissen K, Papenburg BJ, Truckenmüller RK, Carpenter AE, Wessling M, Post GF, Uetz M, Reinders MJ, Stamatialis D, van Blitterswijk CA, de Boer J (October 2011). "An algorithm-based topographical biomaterials library to instruct cell fate". Proceedings of the National Academy of Sciences of the United States of America. 108 (40): 16565–70. doi:10.1073/pnas.1109861108. PMC 3189082. PMID 21949368.
  • Rivron NC, Vrij EJ, Rouwkema J, Le Gac S, van den Berg A, Truckenmüller RK, van Blitterswijk CA (May 2012). "Tissue deformation spatially modulates VEGF signaling and angiogenesis". Proceedings of the National Academy of Sciences of the United States of America. 109 (18): 6886–91. doi:10.1073/pnas.1201626109. PMC 3344996. PMID 22511716.
  • Danoux C, Sun L, Koçer G, Birgani ZT, Barata D, Barralet J, van Blitterswijk C, Truckenmüller R, Habibovic P (March 2016). "Development of Highly Functional Biomaterials by Decoupling and Recombining Material Properties". Advanced Materials. 28 (9): 1803–8. doi:10.1002/adma.201504589. PMID 26689847.

References

  1. ^ Miron, R.J.; Zhang, Y.F. (August 2012). "Osteoinduction: A Review of Old Concepts with New Standards". Journal of Dental Research. 91 (8): 736–744. doi:10.1177/0022034511435260. ISSN 0022-0345.
  2. ^ Yuan H, Fernandes H, Habibovic P, de Boer J, Barradas AM, de Ruiter A, Walsh WR, van Blitterswijk CA, de Bruijn JD (August 2010). "Osteoinductive ceramics as a synthetic alternative to autologous bone grafting". Proceedings of the National Academy of Sciences of the United States of America. 107 (31): 13614–9. doi:10.1073/pnas.1003600107. PMC 2922269. PMID 20643969.
  3. ^ Anderson, Daniel G; Levenberg, Shulamit; Langer, Robert (July 2004). "Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells". Nature Biotechnology. 22 (7): 863–866. doi:10.1038/nbt981. ISSN 1087-0156.
  4. ^ a b c De Boer, Jan. "History of the topochip" (PDF). Jan de Boer Lab.{{cite web}}: CS1 maint: url-status (link)
  5. ^ Unadkat HV, Hulsman M, Cornelissen K, Papenburg BJ, Truckenmüller RK, Carpenter AE, Wessling M, Post GF, Uetz M, Reinders MJ, Stamatialis D, van Blitterswijk CA, de Boer J (October 2011). "An algorithm-based topographical biomaterials library to instruct cell fate". Proceedings of the National Academy of Sciences of the United States of America. 108 (40): 16565–70. doi:10.1073/pnas.1109861108. PMC 3189082. PMID 21949368.
  6. ^ Baker M (November 2011). "Trying out topographies". Nature Methods. 8 (11): 900. doi:10.1038/nmeth.1760. PMID 22167818.
  7. ^ "Distinguished university professors – Research – Maastricht University". maastrichtuniversity.nl. Retrieved 1 February 2018.
  8. ^ "Press release Maastricht University". Maastricht University. 8 April 2016.{{cite web}}: CS1 maint: url-status (link)
  9. ^ "Gravitation". nwo.nl.
  10. ^ "Home – RegMed XB – Regenerative medicine crossing borders". regmedxb.com.
  11. ^ nnadilim. "HOME".
  12. ^ https://www.acti-nl.org/en/homepage?set_language=en since
  13. ^ https://khmw.nl/
  14. ^ "Journal of Tissue Engineering and Regenerative Medicine – Wiley Online Library". Journal of Tissue Engineering and Regenerative Medicine. doi:10.1002/(issn)1932-7005.
  15. ^ "Google Patents". patents.google.com. Retrieved 24 May 2020.
  16. ^ "IsoTis Orthobiologics Archives". SeaSpine.
  17. ^ "IsoTis – Integra Merger". Retrieved 30 September 2018.
  18. ^ "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934". Retrieved 30 September 2018.
  19. ^ "Professor Clemens van Blitterswijk". Kuros Biosciences. Retrieved 24 May 2020.
  20. ^ "News_van Blitterswijk most entrepreneurial scientist in 2012". Retrieved 1 February 2018.
  21. ^ a b "Over de prijs". avondwenm.nl.
  22. ^ "HOME". lspvc.com.
  23. ^ "FUNDS >> Private Franchise". lspvc.com.
  24. ^ https://www.amazon.com/dp/0123708699
  25. ^ "ESB European Society for Biomaterials". esbiomaterials.eu.
  26. ^ https://www.termis.org/chapters_eu.php
  27. ^ "Federaprijs-winnaars – Federa". federa.org.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Clemens_van_Blitterswijk&oldid=958799424"